ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Wang, Xiyong; Zhu, Xiaoyun; Zhang, Hongming; Fan, Xuetong; Xue, Xiulei; Chen, Yan; Ding, Chenbo; Zhao, Jianwen; Wu, Guoqiu

doi:10.7150/jca.19897

Cited by 10 publications

(8 citation statements)

References 21 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of studied biomarkers for efficacy of platinum doublets are not immune biomarkers but tumor biomarkers, studied at a genomic ( 71 ), transcriptomic ( 72 ), or protein level ( 73 ) ( Figure 2 ). However, a few studies have raised the question of TILs in the context of chemotherapy.…”

Section: Baseline Predictors Of Responsementioning

confidence: 99%

Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review

et al. 2020

View full text Add to dashboard Cite

The landscape for medical treatment of lung cancer has irreversibly changed since the development of immuno-oncology (IO). Yet, while immune checkpoint blockade (ICB) revealed that T lymphocytes play a major role in lung cancer, the precise dynamic of innate and adaptive immune cells induced by anticancer treatments including chemotherapy, targeted therapy, and/or ICB is poorly understood. In lung cancer, studies evaluating specific immune cell populations as predictors of response to medical treatment are scarce, and knowledge is fragmented. Here, we review the different techniques allowing the detection of immune cells in the tumor and blood (multiplex immunohistochemistry and immunofluorescence, RNA-seq, DNA methylation pattern, mass cytometry, functional tests). In addition, we present data that consider different baseline immune cell populations as predictors of response to medical treatments of lung cancer. We also review the potential for assessing dynamic changes in cell populations during treatment as a biomarker. As powerful tools for immune cell detection and data analysis are available, clinicians and researchers could increase understanding of mechanisms of efficacy and resistance in addition to identifying new targets for IO by developing translational studies that decipher the role of different immune cell populations during lung cancer treatments.

show abstract

Section: Baseline Predictors Of Responsementioning

confidence: 99%

Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…ACTB is widely used as a reference gene in qPCR analysis [23–25]. However, in this study, the expression of ACTB was significantly down-regulated with a 0.63-fold change in Hcy-treated HUVECs (Fig 2B).…”

Section: Resultsmentioning

confidence: 61%

Identification of suitable reference genes for real-time qPCR in homocysteine-treated human umbilical vein endothelial cells

Xia

Zhang

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

The imbalance in homocysteine (Hcy) metabolism has been implicated in the pathogenesis of human diseases, including cardiovascular and neurodegenerative disorders. When attempting to identify gene expression profiles using quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR), the selection of suitable reference genes is important. Here, the expression levels of 10 commonly used reference genes were assessed for normalization of RT-qPCR in Hcy-treated human umbilical vein endothelial cells (HUVECs) and control cells. The suitability of eight selected candidate genes was comparatively analyzed across the tested samples and separately ranked by four programs, geNorm, NormFinder, BestKeeper, and the ΔCt method. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was the most stable gene in the final ranking using the RankAggreg package. Surprisingly, the β-actin (ACTB) levels decreased significantly in Hcy-treated HUVECs compared with control HUVECs (P<0.05), and further study indicated that Hcy suppressed the expression of ACTB by upregulating the miR-145-5p level in Hcy-treated HUVECs. Our data suggest that GAPDH can be used as a reliable reference gene, while ACTB cannot; normalization of gene expression in RT-qPCR experiments in Hcy-treated HUVECs. The data, which identifies a suitable reference gene in Hcy-treated HUVECs, will contribute to the design of an effective and accurate method for quantitation of gene expression.

show abstract

“…These authors found that only one-the ERCC1 isoform 202-out of four ERCC1 isoforms had a full functional capacity in NER and could be associated with cisplatin resistance in NSCLC [31]. This was confirmed by Wang et al, who showed that ERCC1 could be a prognostic marker in advanced NSCLC treated with platinum-based drugs [36].…”

Section: Nucleotide Excision Repairmentioning

confidence: 81%

Interplay between BRCA1 and GADD45A and Its Potential for Nucleotide Excision Repair in Breast Cancer Pathogenesis

Pietrasik

Zajac

Morawiec

et al. 2020

IJMS

View full text Add to dashboard Cite

A fraction of breast cancer cases are associated with mutations in the BRCA1 (BRCA1 DNA repair associated, breast cancer type 1 susceptibility protein) gene, whose mutated product may disrupt the repair of DNA double-strand breaks as BRCA1 is directly involved in the homologous recombination repair of such DNA damage. However, BRCA1 can stimulate nucleotide excision repair (NER), the most versatile system of DNA repair processing a broad spectrum of substrates and playing an important role in the maintenance of genome stability. NER removes carcinogenic adducts of diol-epoxy derivatives of benzo[α]pyrene that may play a role in breast cancer pathogenesis as their accumulation is observed in breast cancer patients. NER deficiency was postulated to be intrinsic in stage I of sporadic breast cancer. BRCA1 also interacts with GADD45A (growth arrest and DNA damage-inducible protein GADD45 alpha) that may target NER machinery to actively demethylate genome sites in order to change the expression of genes that may be important in breast cancer. Therefore, the interaction between BRCA1 and GADD45 may play a role in breast cancer pathogenesis through the stimulation of NER, increasing the genomic stability, removing carcinogenic adducts, and the local active demethylation of genes important for cancer transformation.

show abstract

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Cited by 10 publications

References 21 publications

Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review

Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review

Identification of suitable reference genes for real-time qPCR in homocysteine-treated human umbilical vein endothelial cells

Interplay between BRCA1 and GADD45A and Its Potential for Nucleotide Excision Repair in Breast Cancer Pathogenesis

Contact Info

Product

Resources

About